Prognostic Markers in Chondrosarcoma: Evaluation of Cell Proliferation and of Regulators of the Cell Cycle by Scully, Sean P. et al.
Sarcoma (1997) 1, 79± 87
ORIGINAL ARTICLE
Prognostic markers in chondrosarcoma: evaluation of cell
proliferation and of regulators of the cell cycle
SEAN P. SCULLY, LESTER J. LAYFIELD & JOHN M. HARRELSON
Section of Musculoskeletal Oncology, Duke University Medical Center, Durham, USA
Abstract
Purpose. The prognosis, treatment principles and prediction of clinical outcome of patients with chondrosarcoma
currently rest on histologic grading which is somewhat ambiguous due to dif® culty in pathologic interpretation of this
neoplasm. Immunohistochemistry, ¯ ow cytometry and oncogene/tumor suppressor gene expression have been examined
as alternative indices to predict the biologic behavior of these tumors. Because of partial successes obtained with ¯ ow
cytometry and because of the improvement in predicting recurrence offered by examining the S-phase fraction, we
undertook the current study to determine if expression of speci® c regulators of the cell cycle would act as prognostic
indicators for these patients.
Subjects/methods. We examined archival pathologic specimens from 39 patients with at least 2 years’ clinical follow-up for
the presence of p53, Rb, src and MIB-1 by immunohistochemistry and correlated this with clinical histories and incidence
of recurrence.
Results. While Rb, p53 and src gene products were identi® ed to a variable extent in these specimens, there was no
prognostic signi® cance to their expression. In contrast, MIB-1, an epitope expressed only during semiconservative
replication and an accepted marker of cell proliferation, served as a signi® cant prognostic indicator. MIB-1 staining was
present in 14.5% of tumor cells in all specimens (range 0± 59%). When MIB-1 staining was examined with respect to
disease recurrence, there was a statistically signi® cant association between staining and histologic grade (p , 0.05) as well
as event-free survival (p , 0.02). Comparing survival curves strati® ed by MIB-1 expression, there was a signi® cant decrease
in event-free survival associated with increasing MIB-1 indices (p, 0.003). Covariates that were associated with event-free
survival include histologic grade (p 5 0.025) and stage (Musculoskeletal Tumor Society) (p 5 0.014). There was no
statistical association with patient age (p5 0.15), tumor size (p 5 0.47), tumor histology (p 5 0.62) or anatomic location
(p 5 0.316).
Discussion. These results indicate that determination of the proliferation index by MIB-1 immunostaining may serve as
a useful adjunct to current histopathologic classi® cation. Patients with a high proliferation index may bene® t from
established adjuvant therapies or experimental approaches including immunotherapy or biologic modulation.
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Introduction
Chondrosarcoma remains a challenge for all disci-
plines of oncology. Histologic grading systems have
traditionally been used for prediction of clinical
behavior.
1 However, the pathologist is not infre-
quently humbled in an attempt to distinguish a
benign cartilaginous lesion from a malignant one.
The radiation therapist and the medical oncologist
have been unable to provide any signi® cant ad-
vances in local or systemic adjuvant treatment.
2 The
patient can be confronted with either local or sys-
temic recurrence for as long as 10 years after the
primary resection. Taken in conjunction, these fac-
tors highlight the need to predict which patients are
at highest risk to fail, and the need for novel ap-
proaches to systemic adjuvant therapies.
Surgical resection remains the primary modality
for the treatment of chondrosarcoma and survival is
most directly related to the adequacy of the surgical
procedure.
3,4 Patients with low-grade chondrosar-
coma that are adequately treated exhibit 5-year sur-
vival rates that approach 90%.
5 In contrast, those
with inadequate surgical treatment and those with
high-grade lesions faired much more poorly with
5-year survival rates of 43%.
6± 8
Several lines of evidence suggest that increased
rates of cell proliferation are associated with poor
prognosis in patients with chondrosarcoma. These
include alterations in mitotic index, ¯ ow cytometry
determined by ploidy and S-phase, Ki-67 staining
and oncogene expression which have been identi® ed
in these patients. We undertook the current study
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in an effort to compare clinical outcome and histo-
logic grade with determination of src, Rb, p53
and MIB-1 markers determined by immunohisto-
chemical analysis. These markers were selected be-
cause they either re¯ ect or in part control the
proliferative activity within the cell cycle. MIB-1
(Ki-67) is expressed in all phases of the cell cycle
except for G0 and some portions of G1. As such, it
represents a good marker of the overall proliferative
activity in a population of neoplastic cells. p53 is
thought to act as a rate limiting protein affects cell
passage through the G1 phase of the cell cycle.
Hence, its absence or a mutation may lead to a
transformed and non-functional phenotype. While
the native form of p53 is short lived, the mutant
forms are thought to persist and be detectable
by immunostaining. The p53 gene is located on
chromosome 17 and appears to cause cell arrest
in the G1 phase.
9± 11 This protein, the deletion of
both wild-type alleles or the presence of a dominant
mutation in one allele can lead to unregulated cell
replication. Several mutations of the p53 gene are
known and are associated with defective protein
products. These protein products lack the normal
proliferation-suppressing properties and have pro-
longed half-lives. The prolonged half-life allows
accumulation of the protein and its detection in
abnormally large amounts by quantitative immuno-
histochemistry.
12
The src gene product is a 60-kDa phosphoprotein
located on the cytoplasmic side of the plasma mem-
brane that functions as a tyrosine kinase. It has been
implicated in the development of avian sarcomas
and may act through phosphorylation of cytoskeletal
proteins such as vinculin. The src oncogene pro-
duces a protein product which, along with ras and
the myc oncogenes, affect cell proliferation and
DNA synthesis.
13 The serine/threonine protein ki-
nase p34 is the major regulator of progression
through the mammalian cell cycle and it appears to
activate src.
14 The precise role of src is unknown but
it may be associated with cytoskeletal alterations
which occur at mitosis and is required for cell
division.
15
Rb-1 is a nuclear protein which is thought to act
as a tumor suppressor gene. This is based on an
absence of expression in retinoblastoma and the
ability to restore a normal phenotype to osteosar-
coma cells with transfection of this gene. The role of
this gene in the etiology of chondrosarcoma is un-
known. The RB (RB-1) gene encodes for a protein,
p105
RB, which has homology with a region of pro-
tein p107. p107 is known to bind to the T antigen
on E1A.
16 pl05
RB is known to bind with double-
stranded DNA in a non-sequence-speci® c manner
and appears to inhibit the stimulation of DNA poly-
merase d . p105
RB also appears to repress myc tran-
scription in some tumor cells.
14 Hence, RB appears
to be an important suppressor gene for the cell
cycle.
This report correlates markers of cell cycle abnor-
malities in patients diagnosed with chondrosarcoma
with histologic grading and vigilant clinical follow-
up. The 39 patients had adequate archival pathology
specimen, non-metastatic disease at the time of
presentation and were treated at a single institution
by a single surgeon over a 21-year period. All pa-
tients underwent resection with negative margins
indicating adequate initial therapy. The data suggest
that similar to histologic grading, proliferation index
derived from MIB-1 staining was a signi® cant prog-
nostic indicator of clinical outcome in these pa-
tients.
Subjects and methods
Subjects
Sixty-six patients were treated at Duke University
Medical Center between 1972 and 1993 for primary
non-metastatic chondrosarcoma. Of these, 39 had
adequate clinical history and suf® cient pathologic
material available to permit evaluation of immuno-
histochemical markers for prognostic signi® cance.
Within this group of 39 patients, biopsies were
performed and clinical staging completed with ra-
diographs, radionucleotide, computed tomography
and magnetic resonance imaging scans when avail-
able. The patients each underwent a wide or radical
resection depending on the speci® cs of the clinical
situation and this was carried out by a single sur-
geon. All surgical margins were negative indicating
adequate initial treatment. The patients were then
followed with clinical examination and serial radio-
graphs for an average of 6.7 years with a minimum
follow-up of 24 months. There were two patients
who presented with local failures and seven patients
who presented with distant failures. Both patients
with local recurrences were patients who subse-
quently developed distant disease. Three patients
received radiation therapy and seven received
chemotherapy post-operatively following either local
or distant recurrence. All patients with distant fail-
ure succumbed to the disease process.
Archival specimens
Surgical specimens obtained at the time of initial
resection were routinely ® xed in 10% neutral
buffered formalin and subsequently paraf® n embed-
ded. The histologic sections for the patients in-
cluded in this study were obtained from the
appropriate paraf® n blocks and were reviewed by
one pathologist (LJL).
Immunohistochemistry
Immunohistochemistry was performed in the Duke
University Medical Center Comprehensive Cancer
Facility as previously described.
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material from all cases was examined by a single
pathologist for sample adequacy. Upon tissue block
retrieval, serial 5 m m sections were mounted on
Fisher1 Plus 1 slides (Fischer, Charlotte, NC,
USA). The slides were dried overnight at 65°Cin an
Imperial oven (Baxter, McGraw Park, IL, USA).
Specimens were deparaf® nized in three successive
xylene baths and were cleared in absolute ethanol.
Slides were then gradually brought to hydration. All
antibodies were diluted in phosphate-buffered saline
with 2% bovine serum albumin (Sigma Chemical
Co., St Louis, MO, USA), pH 7.4 (PBS/BSA). As
negative controls, murine IgG1 (Coulter Source,
Marietta, GA, USA) was diluted 1; 100 and normal
rabbit serum (Grand Island Biochemical Co.,
Grand Island, NY, USA) was diluted 1; 1000 in 2%
PBS/BSA.
MIB-1. The primary antibody used tor MIB-1 de-
termination is a murine monoclonal IgG1 that reacts
with the Ki-67 nuclear antigen (345- and 395-kDa
double band in Western blot analysis) expressed by
proliferating cells.
20 Deparaf® nized slides were incu-
bated in 10 mM citrate buffer, pH 6.0 (Sigma)
for antigen retrieval. Antigen retrieval was carried
out using a 700-W microwave (Quasar, model
MQ7677BW, Elk Grove, IL, USA) as recom-
mended by the antibody manufacturer (Immuno-
tech). Slides were placed in 10 mM citrate solution,
pH 6.0, and microwaved at full power for 5 min.
They were then allowed to cool and microwaved
again for 5 min and were slowly brought to water,
trying to avoid any drastic temperature change.
Assay slides were rinsed with PBS and then placed
in 5% normal goat serum (NGtS) for 20 min.
Excess NGtS was blotted from the slides and the
primary antibodies (IgG1 , MIB-1) diluted 1; 100
were applied and incubated overnight at 4°C for
approximately 18 h. All of the assay incubations
were carried out in a humidity chamber to prevent
solution evaporation. After bringing the slides to
room temperature, they were rinsed in PBS, three
times for 5 min, and incubated with goat anti-mouse
biotinylated antibody (BioGenex, San Ramon, CA,
USA) for 35 min. The slides were rinsed in PBS
three times for 5 min followed by application of
peroxidase-conjugated strepavidin label. The slides
were then developed for 5 min with chromagen
3,39 diaminobenzidene (Sigma) (0.5% diaminoben-
zidine in 0.05 M Tris buffer and 0.6% hydrogen
peroxide). Finally, the assay slides were rinsed in
running tap water for 10 min, counter-stained with
1% methyl green (Sigma), dehydrated in acetone
and cover-slipped in Protexx (Baxter).
Rb, p53, src. Primary antibody directed against p53
(PAb 1801) was obtained from Oncogene Science,
Manhasset, NY, USA (Ab-2) which is an af® nity-
puri® ed IgG1 monoclonal antibody that recognizes a
denaturation-resistant epitope in the human p53
protein located between amino acids 32 and 79.
21
Immunostaining was performed with 1.0 m g ml
2 1
of primary antibody on deparaf® nized slides. The
secondary antibody was biotinylated af® nity-puri® ed
horse anti-mouse IgG (Vector). Sections were devel-
oped in diaminobenzidine solution, rinsed and
counter-stained in 1% methyl green in sodium ac-
etate buffer, pH 5.2.
The antibody to src is a puri® ed IgG (Oncogene
Science, Uniondale, NY, USA). The antibody (titer
of 1; 100) was prepared and run in a fashion de-
scribed for MIB-1. The antibody directed against
Rb protein product was obtained from Oncogene
Science (Uniondale, NY, USA) and run as just
described using a titer of 1; 50.
The quantitation of immunostaining for each of
the markers was determined using a CAS 200
Image Analysis System (Becton Dickinson Cellular
Imaging Systems, San Jose, CA, USA) in combi-
nation with the Quantitative Proliferation Index
CAS Software Program (Becton Dickinson Cellular
Imaging Systems). Quantitation of proliferative in-
dex has been described previously for tumor tissue
sections as the percentage of total nuclear area that
stains positively with antibody. A similar approach
was applied for p53 and Rb.
22 Data obtained by
computerized static image analysis for src were ex-
pressed as a percentage of cellular area positively
stained with monoclonal antibody relative to the
total cellular area. Fifteen ® elds of the tumor were
analyzed at a magni® cation of 3 400. The auto-
mated mean for staining was scored as the represen-
tative index of the neoplasm or it’s components.
Control sections, stained with normal murine IgG1
were prepared in each case, observed by standard
microscopy and analyzed to establish background
immunostaining thresholds. Intra-observer repro-
ducibility was determined as described previously.
23
Statistical analysis
Patients were divided into low and high expression
groups based on the median expression value for
each epitope. For MIB-1 this was . 6.25%, for Rb,
src and p53 . 2%. The segregation into low and
high expression was then used to examine the corre-
lation of these parameters with clinical outcome.
All statistical tests were two-sided with a 5 0.05.
The analysis of variance test with Tukey’s honest
signi® cant difference procedure or two sample t-test
were performed to assess the association of MIB-1
with other prognostic factors. The Kaplan± Meier
24
procedure was used to determine survival curves
and the curves were subsequently compared using
the Wilcoxon rank sum test.
25 c
2 tests were used to
test for association of survival time with covariates.
Parametric tests were supplemented by non-
parametric analysis (Wilcoxon rank sum test,
Kruskal± Wallis test) which yielded similar results.82 S. P. Scully et al.
Table 1. Immunostaining and prognostic signi® cance
Parameter MIB-1 Rb src p53
Qualitative staining 35/39 24/39 19/39 16/39
Quantitative staining 14.5% 4.3% 2.6% 4.7%
Prognostic signi® cance p , 0.01 p 5 0.49 p 5 0.62 p 5 0.67
The immunostaining is presented as the percentage of patients who demonstrated
positive staining for the epitope and also quantitatively as the percentage of cellular area
with positive staining normalized to total cellular area. The prognostic signi® cance was
determined by survival analysis.
Results
Twenty-seven patients underwent a primary attempt
at limb salvage while 12 patients underwent a pri-
mary amputation, all with wide or radical surgical
margins. There were two patients who developed a
local recurrence and were treated with radiation
therapy. Chemotherapy was administered in the
seven patients who developed distant metastasis.
Both of the patients who developed local recur-
rences also developed distant metastasis and ex-
pired.
Immunostaining
The qualitative results of immunostaining of chon-
drosarcoma specimens for the cell cycle regulators,
p53, src and Rb, and for the proliferation index and
their prognostic signi® cance are summarized in
Table 1. The specimens were further studied by
quantitative image analysis in an attempt to make
the evaluation similar to that of the cell proliferation
index. There was no statistically signi® cant corre-
lation between immunostaining results for Rb, p53
and src with histologic type, grade or stage in these
patients.
Twenty-four of the 39 patients demonstrated
positive staining with the Rb antibody (range 0± 23%
with a median of 4.3%). Survival analysis indicated
that there was no prognostic signi® cance to Rb
expression, p 5 0.49 (Fig. 1). Nineteen of 39 pa-
tients demonstrated a positive immunostaining with
the src antibody (range 0± 20% with a median of
2.6%). Kaplan± Meier survival analysis indicated
that the survival in low src expression patients was
equivalent to that in patients expressing higher
amounts of the gene product (Fig. 2). Wilcoxon
rank sum analysis indicates that this difference in
event-free survival is not statistically signi® cant,
p 5 0.62. Sixteen of 39 patients demonstrated an
abnormality in p53 structure on the basis of im-
munostaining (range 0± 47% with a median of
4.7%). Patients with p53 abnormalities demon-
strated a shorter event-free survival than those with
undetectable p53; however, this difference was not
statistically signi® cant, p 5 0.67 (Fig. 3). However,
it should be noted that in four of the six patients
with a dedifferentiated chondrosarcoma, strong p53
staining was observed.
Fig. 1. Survival of patients with chondrosarcoma analyzed by
quantitative immunohistochemical staining for the Rb antigen.
Low Rb staining (solid line) constituted those patients with less
than 2% of cellular area staining positively with respect to total
cellular area, while those with . 2% constituted the high group
(dotted line).
Fig. 2. Survival of patients with chondrosarcoma analyzed by
quantitative immunohistochemical staining for the src antigen.
Low src staining (solid line) constituted those patients with less
than 2% of cellular area staining positively with respect to total
cellular area, while those with . 2% constituted the high group
(dotted line).Cell proliferation in chondrosarcoma 83
Fig. 3. Survival of patients with chondrosarcoma analyzed by
quantitative immunohistochemical staining for the p53 antigen.
Low p53 staining (solid line) constituted those patients with less
than 2% of cellular area staining positively with respect to total
cellular area, while those with . 2% constituted the high group
(dotted line).
Table 2. Proliferation index and histologic grade
Proliferation index
No. of
Histologic grade Mean SE patients
1 8.14 2.8 14
2 7.00 1.7 16
3 37.8 7 9
The correlations between histologic grade and cell
proliferation index are displayed. Histologic grade was
determined following resection of the tumor. The mean of
the proliferation index and the standard error (SE) of the
mean are indicated. The number of patients for each group
is also indicated.
Table 3. Proliferation index and event-free survival
Proliferation index
No. of
Survival Mean SE patients
Disease free 11.3 17.2 32
Recurrence 29.2 15.8 7
p, 0.0242.
The proliferation index is examined for patients who
remained disease free and for those who experienced a
recurrence. The mean and the standard error (SE) of the
mean for proliferation indices are displayed. The number of
patients in each group is also indicated.
MIB-1 immunostaining was used to quantitate a
proliferation index. The mean of the proliferative
index was 14.5% with a range of 0± 59%. There was
a statistically signi® cant association between MIB-1
level and histologic grade, p, 0.05 (Table 2), and
with disease status, p , 0.02 (Table 3). Comparing
survival curves strati® ed by MIB-1 staining, there
was a signi® cant decrease in survival with increasing
MIB-1 indices (p5 0.003; Fig. 4). Cox analysis was
performed and the proliferation index was an inde-
pendent predictor of event-free survival. Covariates
that were associated with survival time included
histologic grade (p5 0.025) and Enneking stage
(p 5 0.0142). There was no association with age
(p 5 0.1556), tumor size (p 5 0.4671), tumor type
(p 5 0.6211) or anatomic location (p 5 0.3160).
The mean proliferation index was examined with
respect to histologic type of chondrosarcoma. There
were 22 classic intramedullary chondrosarcomas, six
dedifferentiated chondrosarcomas and 11 chondro-
sarcomas including those arising in osteochondro-
mas (extraskeletal, clear cell and myxoid variants
were grouped to facilitate comparison). The mean
proliferation index for the intramedullary chon-
drosarcomas was 0.106, that for the dedifferentiated
chondrosarcomas was 0.396 and that for the
grouped variants was 0.086 (Table 4). The dediffer-
entiated chondrosarcomas had a proliferation index
higher than the mean index and also had a lower
event-free survival; however, survival analysis could
not be performed due to limited numbers.
Discussion
Neoplastic cell proliferation, invasion and metas-
tases represent independent and important variables
determining the aggressiveness and behavior of neo-
Fig. 4. Survival of patients with chondrosarcoma analyzed by
quantitative immunohistochemical staining for the MIB-1
antigen. Low MIB-1 staining (solid line) constituted those
patients with less than 6.25% of cellular area staining positively
with respect to total cellular area, while those with . 6.25%
constituted the high group (dotted line)
plastic cell populations. Assessment of molecular or
morphologic markers for these properties of neo-
plastic cell populations would be helpful for predict-
ing the biological behavior of human malignancies.
Traditionally, such markers have been assessed
by morphologic analysis of mitotic ® gure counts,84 S. P. Scully et al.
Table 4. Proliferation index and histologic tumor type
Proliferation index
No. of
Histologic type Mean SE patients
Intramedullary 10.6 2.9 22
Dedifferentiated 39.6 7.8 6
Other 8.6 4.3 11
The proliferation index for each of the histologic subtypes
of chondrosarcoma is displayed. The proliferation index is
displayed as the mean and the standard error (SE) of the
mean for each group. The number of patients with each
diagnosis is also displayed.
but is probably not a major factor contributing to
disease progression.
p53
Recent studies have detected mutations in the p53
gene in some soft tissue sarcomas,
31,32 and
® bromatosis.
33 King reported the development of
chondrosarcoma in patients with Li-Fraumeni syn-
drome implicating p53 mutation in the malignant
transformation of cartilage tissue.
34 Toguchida et al.
examined a group of sarcoma patients and found a
33% incidence of p53 mutation.
32 Wadayama et al.
identi® ed 25% of sarcomas having a p53 mutation,
with ® ve of 20 chondrosarcomas having muta-
tions.
34 This ® nding was associated predominantly
with a dedifferentiated phenotype in each case.
35
Dobashi et al. examined p53 expression in 16 chon-
drosarcoma specimens and found only two patients
with over-expression, however, both of these were
high-grade (III) lesions.
36 Yang et al. found p53
over-expression to be of no prognostic signi® cance
in a series of 54 malignant ® brous histiocytomas.
37
Nawa et al. reported a correlation of p53 staining
with patient survival; however, in multivariate analy-
sis this did not emerge as an independent predic-
tor.
38 Lastly, Simms et al. reported strong staining in
the non-cartilaginous component of dedifferentiated
chondrosarcoma patients in all of the eight patients
examined and only light staining in the cartilaginous
component of the lesion in two patients.
39
The experience of these investigators is consistent
with the data presented in the current study which
shows that four of six dedifferentiated chondrosar-
comas stained positively for p53. As mentioned, this
subset of patients faired poorly from a clinical stand-
point. So while it seems that in these patients p53
mutations may be associated with the dedifferenti-
ated phenotype, they are not a useful prognostic
indicator of chondrosarcoma recurrence in general.
It also suggests that the dedifferentiated component
of chondrosarcoma should be considered a separate
disease process.
rb-1
The retinoblastoma gene (RB) codes for a nuclear
phosphoprotein involved in cell cycle control.
40 The
RB gene is mutated or absent in a variety of malig-
nancies.
15,24,38,41± 47 Monoclonal antibodies have
been developed for identi® cation of the Rb protein
in paraf® n-embedded tissues. Studies correlating Rb
protein status and clinical outcome have demon-
strated that the absence of the Rb protein can be
associated with a poor prognosis
35,48 as well as
resistance to some chemotherapy agents.
49 In the
patients examined in the current study, 27 of 39
patients stained positively for Rb protein. There was
no statistical correlation between Rb-1 staining and
event-free survival.
vascular invasion and histologic analysis of host/
tumor boundary interactions. Recently, a variety of
oncogenes and their protein products have been
recognized as regulators of cell behavior. A variety
of these protein products are known to affect the cell
cycle and hence represent control substances for cell
proliferation. Others like MIB-l appear to be useful
as markers of overall cell proliferation. The regu-
lation of cell proliferation by oncogene protein prod-
ucts is complex and at present is only partially
understood. We chose to study the predictive value
of the cell proliferation index as determined by
MIB-1 as well as the predictive value of quantitation
of certain oncogene products known to have regula-
tory functions in the cell proliferation cycle.
src
It is known that cells transformed by src will be
inhibited from entering into the S-phase when anti-
ras antibodies are injected into cell cultures. Such
observations suggest that src oncogene transforms
cells via a pathway involving ras. Other tumor sup-
pressor genes including p53 and RB-1 activate path-
ways that converge downstream of the ras oncogene
point of control. The src family of genes codes for
proteins with tyrosine kinase activity.
26 This activity
is normally inhibited in vivo by phosphorylation of
Tyr 527. In intact cell, the targets of src involved in
regulating cell proliferation have not been
identi® ed
27 but src may play an indirect role in cell
cycle regulation by its ability to phosphorylate p34.
28
In studies with mice, src appears to be essential for
bone formation, thus implicating a physiologic role
in normal mesenchymal tissue. Early reports had
implicated myc and src oncogenes in the prolifera-
tion and synthesis of speci® c matrix components in
chondroblasts.
29 Zhu et al. were unable to detect src
gene transcription using Northern hybridization.
30
We were able to identify 19 of 39 patients with
immunohistochemical evidence of src gene product
translation but there was no statistical correlation
with clinical outcome. We conclude that the role of
the src gene product in the etiology and clinical
behavior of chondrosarcoma is currently unknownCell proliferation in chondrosarcoma 85
MIB-1
The cell proliferation index has been determined
in the past with thymidine labeling,
50 5-bromo-
deoxyuridine labeling,
51 ¯ ow cytometry
52± 54 and by
quantitation of nucleolar organizer regions.
55 As-
sessment of the growth fraction may also be per-
formed on frozen sections by Ki-67 immunostaining
which reacts with a proliferation associated antigen
expressed in all cells not in G0 or portions of the G1
phase of the cell cycle.
56,57 More recently, several
antibodies have been described that demonstrate
proliferating cells in formalin-® xed tissue including
Ki-67, PCNA and MIB-1.
58± 60 MIB-1 staining has
been demonstrated to have prognostic in¯ uence in
patients with breast carcinoma,
61,62 ovarian cancer,
63
but a recent study examining benign and malignant
® brohistiocytic lesions demonstrated only a limited
role for MIB-1 in distinguishing between these le-
sions.
64 In contrast, Yang et al. did show that the
proliferation index as determined by Ki-67 im-
munostaining had prognostic value in ® brous le-
sions.
65 Our data supported the usefulness of the
proliferation index (MIB-1) as a signi® cant prognos-
tic indicator for chondrosarcoma: a higher prolifera-
tion index was associated with a lower event-free
survival (p . 0.01).
DNA analysis by ¯ ow cytometry has been ex-
plored in the past as a means of predicting biologic
behavior of chondrosarcoma.
66 Alho et al. reported a
statistically signi® cant association between malig-
nant behavior of the tumor and aneuploid content.
67
A later report by the same senior investigator ex-
tended this analysis over a larger patient population
with similar results.
67 In analysis by ¯ ow cytometry,
it can be dif® cult to differentiate DNA ploidy abnor-
malities from changes in DNA content associated
with the cell cycle. More recently, an independent
investigator has reported that the S-phase fraction
rather than aneuploidy correlates most closely with
biologic behavior.
69 The number of tumors exam-
ined was small (four benign and four malignant
cartilaginous tumors), but the data suggest that the
proportion of cells that have entered the cell cycle
was prognostically important. An alternative means
of determining the fraction of cells entering the cell
cycle is to examine the expression of the Ki-67
epitope. Nawa et al. have recently reported a corre-
lation of MIB-1 staining with histologic grade and
event-free survival.
38 Nawa et al. found a mean
proliferation index of 3.2% for grade I lesions,
14.7% for grade II lesions and 16.4% for grade III
lesions. This is consistent with the distribution of
proliferation indices that was observed in the cur-
rent study and indicates that the proliferative index
serves as a prognostic indicator for chondrosarcoma.
It is interesting that the cell proliferation rate
appears to be an important prognostic factor in
patients with chondrosarcoma yet two of the
proteins identi® ed in cell cycle control do not ap-
pear to be involved. This leads one to speculate that
there are additional mechanisms regulating the pro-
liferative rate in cartilaginous tissues.
Concluding remarks
The data presented in this report indicate that the
proliferation rate of chondrosarcoma cells serves as
a prognostic indicator for disease recurrence and
clinical outcome. Tumors with a high rate of cell
proliferation have a worse prognosis and patients
af¯ icted with these tumors demonstrate a shorter
event-free survival. MIB-1 may serve as a useful
clinical adjunct to histopathologic grading and ¯ ow
cytometry in the staging and treatment of patients
with chondrosarcoma. Prognosis was not correlated
to the level of regulatory protein products (oncoge-
nes, Rb-1, src, p53) in our experience. Perhaps
quantitation of other regulatory oncogenes of cell
proliferation as well as markers of cell± cell cohesion
or invasiveness might yield results more predictive
of tumor behavior and correlate with the prolifera-
tive index. A high proliferation index at the time of
biopsy may lead clinicians to consider existing adju-
vant therapies as these tumors may be more respon-
sive because of their increased rate of DNA
synthesis. Alternatively, future adjuvant therapies
such as immunotherapy or biologic modulation may
be appropriate for these patients who are at high risk
of recurrent disease.
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